After Motorola Inc. (NYSE: MOT)'s annual shareholder meeting last night, the company's bid to thwart billionaire Carl Icahn from attaining a seat on the company's board of directors must have worked. Icahn was pressuring to become installed on the board of the telecom and cellphone maker in his attempt to re-shape management and start a turnaround of the company. Clearly, Icahn was not pleased with the leadership of company CEO Ed Zander and would have heavily lobbied to get rid of him if he had won a board seat.
But, that did not happen. Icahn was not elected to the Motorola board and MOT shares tanked a bit his morning when trading started, as a result. As Icahn's bid to have Motorola take on more debt and return more to shareholders fell by the wayside, it also gave Zander more time and room to operate and get Motorola back on the road to hot products, rapid development and marketing and profitability -- something lacking from the company last quarter as the first quarterly loss since 2004 was put on the books.
This action buys Zander some precious time, but the road won't be easy. Competitors like Samsung and Nokia Corp. (NYSE: NOK) are eating away at Motorola's marketshare every day and the success of the Motorola RAZR is now fading sharply from view. It may take another market-disrupting product like the RAZR to get Motorola back on target again -- but is that even possible with the current technological state of the modern wireless phone? Doubtful -- there are few (if any) paradigm shifts left unless we all want to start implanting phones into our bodies or something. Perhaps Motorola should purchase a medical device company?
Last updated: February 10, 2012: 12:00 PM
Hot Stocks
DailyFinance Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
Benzinga Headlines
- Don't Bank on Barclays
- GSV Capital Punished for Expanding Facebook Investment
- Chesapeake Gently Lets Go of Gas
- How to Profit off Addicts
- The Pepsi Challenge for 8,700 People is to Find a New Job
TheFlyOnTheWall.com Headlines
- Morgans Hotel management to meet with JMP Securities
- JPMorgan management to meet with Sterne Agee
- International Paper, Temple-Inland settle with DOJ over merger
- W.R. Grace management to meet with CL King
- Compuware management to meet with Jefferies
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Savings Experiment: Snow Removal
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?

